HomeAI · summaries
Storia in 4 fonti
Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?
Novartis, BMS reportedly halt trials; first serious blow to burgeoning field
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily…
- ·
endpoints.news
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
